Health Care • Biotechnology: Pharmaceutical Preparations
$18.57 ▲ +0.21
(+1.14%)
MKT CAP: $605.6M • VOL: 117.7K
52W L $6 52W H $29
ROARABLE / RQD
D- • 43/100
PIOTROSKI
2 / 9
NVCT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$27.6M | -$19.8M | -$22.9M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$26.4M | -$19.0M | -$22.3M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$16.0M | -$12.2M | -$16.0M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$16.0M | -$12.2M | -$16.0M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $31.6M | $18.5M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $18.4M | $9.7M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR NVCT.